Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board
11 Julho 2023 - 9:30AM
Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY®
Robotic Surgical System, the first single-use endovascular robotic
surgical system, today announced that Irene Bargellini, M.D., an
interventional radiologist and Chair of the Diagnostic and
Interventional Radiology Department at Candiolo Cancer Institute in
Turin, Italy, has joined the Company’s Scientific Advisory Board
(SAB). Dr. Bargellini is the latest expansion of Microbot’s global
presence with highly esteemed medical experts in large addressable
markets.
Dr. Bargellini’s primary clinical and scientific
focus is on oncologic imaging and interventional oncology, with
reference to liver imaging and liver tumors’ loco-regional and
systemic therapies.
“It is encouraging that leading interventional
radiologists continue to join Microbot as it embarks on the steps
towards the commercialization of the system,” commented Eyal Morag,
MD, Chief Medical Officer. “In addition to leveraging Dr.
Bargellini’s expertise to achieve this goal, we also recognize that
Italy represents an important and potentially large addressable
market for the LIBERTY Robotic Surgical System. Dr. Bargellini is a
potential future user, who we believe could support our entry into
the Italian market upon regulatory clearance.”
“I believe it’s important to support technology
that can advance medicine and improve patient outcomes, and having
experienced the system first-hand, I am eager to lend my
capabilities and contribute to the system’s success,” commented Dr.
Bargellini. “Additionally, I believe the potential of the LIBERTY
Robotic Surgical System to reduce the level of radiation exposure
makes it possible for more women to pursue a career as
interventional radiologists, while not potentially endangering
their health and/or ability to have children.”
Dr. Bargellini is Member of the Executive
Committee of Italian Society of Radiology (SIRM), fellow of the
European Society of Gastrointestinal and Abdominal Radiology
(ESGAR) and the Cardiovascular and Interventional Radiology Society
in Europe (CIRSE), and member of the European Society of Radiology
(ESR), European Society for the Study of the Liver (EASL) and
International Liver Cancer Association (ILCA). She serves as
reviewer of several national and international journals and is
Member of the Editorial Board of European Radiology and
Cardiovascular and Interventional Radiology journals. Dr.
Bargellini has authored and co-authored over 100 articles in
peer-review journals, is co-author of several book chapters, and
has given over 300 invited lectures in national and international
meetings.
For a complete list and background on the
members of the SAB, please use this link About - Microbot
Medical
About Microbot
Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The LIBERTY® Robotic Surgical System aims to
improve the way surgical robotics are being used in endovascular
procedures today, by eliminating the need for large, cumbersome,
and expensive capital equipment, while reducing radiation exposure
and physician strain. The Company believes the LIBERTY® Robotic
Surgical System’s remote operation has the potential to be the
first system to democratize endovascular interventional
procedures.Further information about Microbot Medical is available
at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
LIBERTY®, the outcome of its studies to evaluate LIBERTY®, whether
the Company’s core business focus program and cost reduction plan
are sufficient to enable the Company to continue to focus on its
LIBERTY technology while it stabilizes its financial condition and
seeks additional working capital, any failure or inability to
recruit and retain physicians and clinicians to serve as primary
investigators to conduct regulatory studies which could adversely
affect or delay such studies, uncertainty in the results of
pre-clinical and clinical trials or regulatory pathways and
regulatory approvals, uncertainty resulting from the COVID-19
pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC), which are available
on the SEC’s web site at www.sec.gov. Microbot Medical disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
Investor Contact:
Michal Efraty+972-(0)52-3044404IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024